BRPI0111060B8 - composição adequada para injeção através de uma agulha em um hospedeiro e métodos para sua preparação - Google Patents

composição adequada para injeção através de uma agulha em um hospedeiro e métodos para sua preparação

Info

Publication number
BRPI0111060B8
BRPI0111060B8 BR0111060A BR0111060A BRPI0111060B8 BR PI0111060 B8 BRPI0111060 B8 BR PI0111060B8 BR 0111060 A BR0111060 A BR 0111060A BR 0111060 A BR0111060 A BR 0111060A BR PI0111060 B8 BRPI0111060 B8 BR PI0111060B8
Authority
BR
Brazil
Prior art keywords
injection
suspension
viscosity
preparation
needle
Prior art date
Application number
BR0111060A
Other languages
English (en)
Other versions
BRPI0111060B1 (pt
BR0111060A (pt
Inventor
Michael Ramstack J
M Hotz Joyce
Gary I Riley M
L Johnson Olufunmi
E Zale Stephen
Original Assignee
Alkermes Controlled Therapeutics Inc
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24310496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0111060(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Controlled Therapeutics Inc, Alkermes Pharma Ireland Ltd filed Critical Alkermes Controlled Therapeutics Inc
Publication of BR0111060A publication Critical patent/BR0111060A/pt
Publication of BRPI0111060B1 publication Critical patent/BRPI0111060B1/pt
Publication of BRPI0111060B8 publication Critical patent/BRPI0111060B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

"preparação de suspensões injetáveis tendo injetabilidade aperfeiçoada". a invenção refere-se a composições injetáveis tendo injetabilidade aperfeiçoada. as composições injetáveis incluem micropartículas em um veículo aquoso para injeção tendo uma viscosidade de pelo menos 20 cp a 20 <198>c. a viscosidade aumentada do veículo para injeção que constitui a fase fluida da suspensão reduz significativamente as falhas de injetabilidade in vivo. as composições injetáveis podem ser feitas através de mistura de micropartículas secas com um veículo aquoso para injeção a fim de formar uma suspensão e, então, mistura a suspensão com um agente para intensificação de viscosidade a fim de aumentar a viscosidade da fase fluida da suspensão até o nível desejado para injetabilidade aperfeiçoada.
BR0111060A 2000-05-25 2001-04-19 composição adequada para injeção através de uma agulha em um hospedeiro e métodos para sua preparação BRPI0111060B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/577,875 US6495164B1 (en) 2000-05-25 2000-05-25 Preparation of injectable suspensions having improved injectability
US09/577,875 2000-05-25
PCT/US2001/012652 WO2001091720A2 (en) 2000-05-25 2001-04-19 Preparation of injectable suspensions having improved injectability

Publications (3)

Publication Number Publication Date
BR0111060A BR0111060A (pt) 2003-04-15
BRPI0111060B1 BRPI0111060B1 (pt) 2019-04-16
BRPI0111060B8 true BRPI0111060B8 (pt) 2021-05-25

Family

ID=24310496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111060A BRPI0111060B8 (pt) 2000-05-25 2001-04-19 composição adequada para injeção através de uma agulha em um hospedeiro e métodos para sua preparação

Country Status (27)

Country Link
US (7) US6495164B1 (pt)
EP (4) EP3095442B1 (pt)
JP (1) JP4502355B2 (pt)
KR (1) KR100810480B1 (pt)
CN (1) CN100453067C (pt)
AT (1) ATE363891T1 (pt)
AU (2) AU2001255463B2 (pt)
BG (1) BG66023B1 (pt)
BR (1) BRPI0111060B8 (pt)
CA (1) CA2406536C (pt)
CY (3) CY1107441T1 (pt)
CZ (1) CZ301359B6 (pt)
DE (1) DE60128798T2 (pt)
DK (3) DK2269577T3 (pt)
ES (3) ES2286118T3 (pt)
HK (4) HK1054319A1 (pt)
HU (1) HU228587B1 (pt)
IL (1) IL152767A (pt)
IS (1) IS2471B (pt)
MX (1) MXPA02011543A (pt)
NO (1) NO334660B1 (pt)
NZ (1) NZ522335A (pt)
PL (1) PL204298B1 (pt)
PT (2) PT2269577E (pt)
RU (1) RU2002135641A (pt)
SI (2) SI2269577T1 (pt)
WO (1) WO2001091720A2 (pt)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
KR100525189B1 (ko) * 2002-10-10 2005-10-31 메디칸(주) 고체를 이용한 생체 부피 대체를 위한 주사용 소재
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2510196C (en) 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
AU2004262507B2 (en) * 2003-03-04 2010-02-18 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
PT1660009E (pt) 2003-09-03 2015-05-18 Miscon Trading S A Métodos para o tratamento da endometriose
US7169180B2 (en) * 2003-09-03 2007-01-30 Brennan William A System and method for breast augmentation
US8092527B2 (en) * 2003-09-03 2012-01-10 Brennan William A System and method for breast augmentation
US7906125B2 (en) * 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
DE602004017342D1 (de) * 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
WO2005042026A1 (ja) * 2003-10-31 2005-05-12 Wakamoto Pharmaceutical Co., Ltd. 可逆性熱ゲル化水性組成物
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US8263109B2 (en) * 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
EP2347762B1 (en) 2005-08-19 2019-05-08 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP3058972A1 (en) 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX337286B (es) 2007-05-25 2016-02-22 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8795694B2 (en) * 2007-07-26 2014-08-05 Aqtis I.P. B.V. Microparticles comprising PCL and uses thereof
NZ582415A (en) * 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
WO2009056990A2 (en) * 2007-08-21 2009-05-07 Actavis Group Ptc Ehf Paliperidone polymorphs
US9987221B2 (en) * 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
BRPI0819175A2 (pt) * 2007-11-05 2015-05-05 Bausch & Lomb Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2829265B1 (en) 2008-04-28 2016-08-24 Zogenix, Inc. Novel formulations for treatment of migraine
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
JP2012501966A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
ES2770273T3 (es) * 2008-06-27 2020-07-01 Tepha Inc Administración inyectable de micropartículas y composiciones para ello
FI2341905T4 (fi) 2008-09-04 2023-12-04 Amylin Pharmaceuticals Llc Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia
US20100063879A1 (en) * 2008-09-05 2010-03-11 Yellowpages.Com Llc Systems and Methods to Selectively Provide Information Based on User Interest
WO2010068866A2 (en) * 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
KR101936968B1 (ko) 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
KR101811917B1 (ko) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EA030318B1 (ru) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CA2879942C (en) 2012-07-26 2020-06-02 Camurus Ab Opioid formulations
CN104812381B (zh) 2012-09-17 2018-01-26 辉瑞大药厂 用于制备治疗性纳米颗粒的方法
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2015123272A1 (en) * 2014-02-11 2015-08-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
SG11201607645TA (en) 2014-03-14 2016-10-28 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3871709A1 (en) 2014-08-06 2021-09-01 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
MX2017002271A (es) 2014-08-28 2017-05-22 Massachusetts Gen Hospital Composiciones y metodos para el tratamiento de trastornos neurologicos.
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3233056B1 (en) 2014-12-15 2023-11-15 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
EP3978011A1 (en) 2015-05-22 2022-04-06 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016198351A1 (en) 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
EA038755B1 (ru) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки
EP3377041B1 (en) 2015-11-16 2023-10-25 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
SG10201913504XA (en) 2016-02-26 2020-03-30 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US10350200B2 (en) * 2017-01-23 2019-07-16 Southwest Research Institute Aqueous suspensions of oximes for autoinjectors
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
CA3064840A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US10568842B2 (en) * 2017-08-18 2020-02-25 Lance L. Gooberman Anti-inflammatory pharmaceutical compositions and methods of administration
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
AU2019362730B2 (en) * 2018-10-15 2022-10-20 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
BR112022013270A2 (pt) * 2020-01-03 2022-09-06 Privo Tech Inc Sistemas e composições farmacêuticas para tratamento por injeção direta de uma população alvo de células
BE1028769B1 (nl) * 2020-11-02 2022-05-31 Flanders Color Nv Watergedragen vloeibare spoellak
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN114146020B (zh) * 2022-02-10 2022-04-29 中国远大集团有限责任公司 一种注射美容产品及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (pt) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3700215A (en) * 1970-10-21 1972-10-24 Hardman Inc Mixing and dispensing device
JPS523342B2 (pt) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
IL51791A0 (en) * 1976-04-14 1977-05-31 Exxon Research Engineering Co New injectable medicinal compositions
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
EP0471036B2 (en) 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US6537574B1 (en) * 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
ATE193037T1 (de) 1992-02-28 2000-06-15 Collagen Corp Hochkonzentrierte homogenisierte kollagenzusammensetzungen
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
MX9301823A (es) 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
KR100333115B1 (ko) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 항정신병약함유서방성마이크로스피어및이의제조방법
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ES2236700T3 (es) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
ES2172574T5 (es) 1993-11-19 2012-11-29 Alkermes, Inc. Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
CN1156961A (zh) * 1995-06-09 1997-08-13 欧罗赛铁克股份有限公司 产生长效局部麻醉的制剂和方法
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5985320A (en) * 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2000039867A (ja) * 1998-05-18 2000-02-08 Fujitsu Ltd プラズマディスプレイ装置およびプラズマディスプレイパネルの駆動方法
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
CN100387228C (zh) 1999-08-27 2008-05-14 布鲁克伍德药品公司 可注射的美沙酮、部分类鸦片激动剂或类鸦片拮抗剂微粒组合物及其用途
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability

Also Published As

Publication number Publication date
US20080044485A1 (en) 2008-02-21
DK2269577T3 (en) 2016-06-27
SI2269577T1 (sl) 2016-09-30
DK1754469T3 (en) 2016-06-27
EP2269577B1 (en) 2016-03-16
NO20025164L (no) 2002-11-25
US20140193507A1 (en) 2014-07-10
US7799345B2 (en) 2010-09-21
DK1283699T3 (da) 2007-10-01
CZ20023848A3 (cs) 2003-05-14
CY1117734T1 (el) 2017-05-17
CA2406536C (en) 2009-12-22
ES2572877T3 (es) 2016-06-02
HK1152660A1 (zh) 2012-03-09
KR100810480B1 (ko) 2008-03-07
PL365195A1 (en) 2004-12-27
ES2286118T3 (es) 2007-12-01
EP2269577A2 (en) 2011-01-05
US6495164B1 (en) 2002-12-17
CN100453067C (zh) 2009-01-21
EP1283699A2 (en) 2003-02-19
BRPI0111060B1 (pt) 2019-04-16
WO2001091720A2 (en) 2001-12-06
CY1117652T1 (el) 2017-05-17
BR0111060A (pt) 2003-04-15
IL152767A (en) 2008-12-29
EP1754469A1 (en) 2007-02-21
MXPA02011543A (es) 2004-08-12
US7371406B2 (en) 2008-05-13
KR20030020285A (ko) 2003-03-08
HK1056321A1 (en) 2004-02-13
US20040208938A1 (en) 2004-10-21
ES2574823T3 (es) 2016-06-22
HK1103346A1 (zh) 2007-12-21
NZ522335A (en) 2003-08-29
US20100303900A1 (en) 2010-12-02
US20080044478A1 (en) 2008-02-21
CY1107441T1 (el) 2012-12-19
RU2002135641A (ru) 2004-07-20
NO20025164D0 (no) 2002-10-28
CN1430501A (zh) 2003-07-16
HK1054319A1 (en) 2003-11-28
PL204298B1 (pl) 2009-12-31
CA2406536A1 (en) 2001-12-06
AU2001255463B2 (en) 2004-11-04
IS6595A (is) 2002-10-28
IS2471B (is) 2008-12-15
PT1283699E (pt) 2007-06-22
EP1754469B1 (en) 2016-03-23
EP3095442A1 (en) 2016-11-23
US6667061B2 (en) 2003-12-23
HU228587B1 (en) 2013-04-29
WO2001091720A3 (en) 2002-05-23
BG66023B1 (bg) 2010-11-30
HUP0302283A2 (hu) 2003-10-28
IL152767A0 (en) 2003-06-24
US20030113380A1 (en) 2003-06-19
HUP0302283A3 (en) 2007-02-28
ATE363891T1 (de) 2007-06-15
JP2003534366A (ja) 2003-11-18
BG107288A (bg) 2003-06-30
SI1754469T1 (sl) 2016-09-30
CZ301359B6 (cs) 2010-01-27
DE60128798D1 (de) 2007-07-19
JP4502355B2 (ja) 2010-07-14
AU5546301A (en) 2001-12-11
NO334660B1 (no) 2014-05-12
EP1283699B1 (en) 2007-06-06
DE60128798T2 (de) 2007-10-31
PT2269577E (pt) 2016-06-14
EP2269577A3 (en) 2011-11-30
EP3095442B1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
BRPI0111060B8 (pt) composição adequada para injeção através de uma agulha em um hospedeiro e métodos para sua preparação
BR9901075A (pt) Composição elastomérica e processos para preparar a mesma, para plastificar um elastÈmero, e, para melhorar a processabilidade de um elastÈmero.
BR0107052A (pt) Processo de fratura de reservatório em tempo real
BR9705617A (pt) Cateter plástico composto de uma peça revestido de cânula
BR0304134A (pt) Métodos para produção de fluidos de tratamento e de fraturamento, para tratar e para fraturar uma formação subterrânea, e para realizar uma pluralidade de tratamentos de formação subterrânea, e, composição para um fluido de tratamento
BR0311877A (pt) Preparações ácidas de insulina com estabilidade aperfeiçoada
BR9811461A (pt) Produto de limpeza na forma de gel para vasos sanitários
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
BRPI0414128A (pt) sistema e método para aumento de mamas
BR0111257A (pt) Formulação, e, uso de uma formulação
BR0006810A (pt) Composição compreendendo um amido, e, fibra oufilamento compreendendo amido
BR9809483A (pt) Composição de reticulação, processo para faze-la, e, uso da mesma.
BR0309788A (pt) Método de incorporação de um material em um aglutinante consolidável
BR0214602A (pt) Método de produção de um tablete detergente, tablete detergente, e, componente de argila adequado para uso em uma formulação detergente
BR0312033A (pt) Formulações para depósito de curta duração
BR0213278A (pt) Composição vedante e seu uso
DE69837159D1 (de) Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml
BR9908109A (pt) Formulações de polìmeros perolares
BR0113690A (pt) Método para preparar uma composição condicionadora de tecido, e, composição condicionadora de tecido
BR9815885A (pt) Composição de condicionamento de cabelo.
BRPI0501838A (pt) mina colorida apagável
KR950002789A (ko) 개선된 저점도의 고농도 황산바륨 조영제 및 그의 제조방법
BR0009173A (pt) Utilização de um agente anti-lixiviação
PT91760A (pt) Processo para a preparacao de primarios aquosos a base de copolimeros contendo grupos amino e destes copolimeros

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/00

Ipc: A61K 9/10 (2010.01), A61K 9/08 (2010.01), A61K 9/5

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALKERMES CONTROLLED THERAPEUTICS INC. (US) , ALKER

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/04/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 19/04/2021